Gill Jennings & Every
Gill Jennings & Every is a leading intellectual property firm based in London and Munich. We provide the ideal combination of legal, technical and commercial expertise to help turn your innovations, brands and designs into commercial success.
We understand the importance of intellectual property to your business and by providing clear, creative and expert advice we can assist you to protect, exploit and manage your IP assets to maximise their value.
GJE‘s dedicated investor group is focused on understanding the needs of today’s investors, and has substantial experience in advising venture capital and business angel groups who are evaluating investment targets, particularly in knowledge intensive businesses. Having acted for many successful companies during IPOs or trade sales, we understand the requirements at later stages of funding and exit, and so are well placed to offer continuing IP advice to maximise the value of an initial investment.
What we do
- Development of IP strategy and “investor readiness” aligned to an investee’s business or exit plan
- IP due diligence for transactions/fundraising
- Competitor landscaping, IP searches and freedom-to-operate opinions
- IP audit to clearly identify IP, its ownership and value
- Brand and domain name protection
- Management of patent and trade mark portfolios
The hidden risks of IP can have an enormous commercial impact for both investors and companies alike. Managing IP risks and developing an explicit IP strategy that deals with these risks in a cost-effective and responsible manner, will repay itself in the longer term. Please get in touch to discuss your business and its IP.
|Services Provided||Intellectual Property|
|Does this organisation invest or provide business funding?||No|
|Sectors Considered||Aerospace and Defence, Automobile and Transport, Clean Tech and Eco Innovation, Computing and Electronics, Consumer and e-commerce, Consumer Technology, Fashion and Design, Fin Tech, Food and Drink, Healthcare, Med Tech and Digital Health, Internet of Things, Life Sciences, Materials and Manufacturing, Mobile and Telecoms, Renewables and Energy, Retail|
|No. of opportunities selected each year||n/a|
|Company Initial Fee||n/a|
|Company Success Fee||n/a|
|Company Advisory Fee||n/a|
|Investor Membership Fee||n/a|
Imago BioSciences announces $40M Series B financing led by Omega Funds
On 21 March, Imago BioSciences, Inc., a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, announced...
GJE client Lundbeckfonden Emerge co-invests $50 million in SNIPR Biome Limited
On 11 March 2019, Lundbeckfonden Emerge announced the completion of a joint $50 million investment in...